IMRX Short Volume
Immuneering Corporation (IMRX) operates in the Healthcare sector, specifically the Biotechnology industry, with a market capitalization near $195.3M, listed on NASDAQ, employing roughly 54 people, carrying a beta of 0.36 to the broader market. Immuneering Corporation, a biopharmaceutical company, focuses on the oncology and neuroscience product candidates. Led by Benjamin J. Zeskind, public since 2021-07-30.
Short volume measures the number of shares sold short on a given day as reported by FINRA. Tracking short volume relative to total volume helps identify unusual bearish sentiment or short-squeeze potential.
- Latest Date
- 2026-05-15
- Short Volume
- 185.0K
- Total Volume
- 268.3K
- Short %
- 68.94%
- 30-Day Avg Short %
- 52.09%
Showing 30 days of FINRA short volume data for Immuneering Corporation.
Learn how short volume is reported and how to read the data →
Frequently asked IMRX short volume questions
- What is the daily IMRX short volume?
- As of May 15, 2026, Immuneering Corporation (IMRX) short volume is 185.0K shares against 268.3K total reported volume, or 68.94% short-side. Short volume measures shares sold short during the day; it is flow, not inventory.
- How is IMRX short volume reported?
- FINRA publishes the Daily Short Sale Volume File for trades reported to FINRA TRFs and the FINRA/Nasdaq ADF on a T+1 basis. The headline figure is the count of shares that printed at the short-sale or short-exempt tick across all reporting venues for the symbol; each exchange separately publishes its own daily short-sale data file.
- What does IMRX short volume tell options traders?
- Daily short-sale flow is one input that helps disambiguate dealer-hedging activity from directional bear flow when the chain shows fresh customer call inventory. It is not a clean MM-only proxy: the headline number mixes directional shorting, options-MM delta-hedging, ETF-creation arbitrage, and convertible-arb hedging. Cross-check against gamma-exposure and OI changes for a cleaner read.